Cohance Lifesciences Limited has informed the Exchange regarding a press release dated August 13, 2025, titled "Press Release".
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences reported its first full quarter results under the new brand, with Q1FY26 revenue of ₹5,493 million, up 13% year-on-year. Excluding a temporary inventory destocking effect in Pharma CDMO, underlying revenue growth exceeded 25%. Gross margins expanded to 73.0% from 68.4% a year ago, and adjusted EBITDA came in at ₹1,314 million (23.9% margin). Niche technology revenues crossed 20% of total sales (up from mid-teens in FY25), with strong traction in ADC payload-linkers, oligonucleotides, and high-containment APIs. The company added four new large global innovator customers, secured a US FDA approval (with Priority Review and Breakthrough Therapy Designation) for a partner's small molecule program, and is building a $10 million bioconjugation suite in Princeton and a ₹230 million oligonucleotide facility in Hyderabad.
This is a constructive update for shareholders — solid top-line growth, expanding margins, and meaningful progress in higher-value niche technologies suggest the Cohance rebrand is translating into operational momentum. The destocking drag is flagged as temporary, and new leadership (CDMO CEO) plus a global advisory board point to a clear strategic direction, which could support investor confidence and stock sentiment.